IPO market showed significant improvement in July. There were 13 main board IPO in July including of Kalpataru Limited, Globe Civil Projects Limited, Ellenbarrie Industrial Gases Limited, Sambhv Steel Limited, HDB Financial Services Limited, Indogulf Cropsciences Limited, Crizac Limited, Travel Food Services Limited, Smartworks Coworking Spaces Limited, Anthem Biosciences Limited, Indiqube Spaces Limited, GNG Electronics Limited and Brigade Hotel Ventures Limited against 06 main board IPOs in June 2025. There were 18 SME IPOs in July 2025 as against 03 SME IPOs in June 2025.
Anthem Biosciences Limited:
|
About the Company |
Incorporated in 2006, Anthem Biosciences Limited is a technology-driven CRDMO with end-to-end capabilities in drug discovery, development, and manufacturing for both New Chemical Entities (NCEs) and New Biological Entities (NBEs). The company serves over 550 customers in more than 44 countries, and has executed more than 8,000 projects across pharmaceuticals, biotechnology, and specialty chemicals. The firm reported a revenue of Rs 1845 crore and PAT of 451 Crore in FY25, marking a significant increase from Rs. 1419 crore in revenue and Rs. 367 crore in PAT in FY24. |
|
Funds Utilization |
The IPO is entirely an Offer for Sale, and the proceeds will go to the selling shareholders after deducting offer-related expenses and taxes. |
|
Anchor Investor & Selling Shareholders |
The company raised Rs. 1016 crore from anchor investors, with promoter and selling shareholder Viridity Tone LLP, an investment entity of True North Co, offloading part of its stake through the OFS. |
|
IPO Performance |
The Rs. 3396 Crore IPO comprised of entirely offer for sale of 5.96 Crore shares. The issue was subscribed over 67.42 times, with QIB’s subscribing the most at 192.80 times to the issue. Shares of Anthem Biosciences Limited made a stellar debut on the bourses on 20th June, and got listed at Rs. 723 on NSE and BSE, i.e. a premium of 27 % over the issue price of Rs 570. |
Funds Mobilization by Corporates (Rs. In Crore)
|
Particulars |
May-25 |
June-25 |
|
I. Equity Issues |
10,916 |
30,697 |
|
a. IPOs (i+ii) |
5,684 |
9,526 |
|
i. Main Board |
5,276 |
8,575 |
|
ii. SME Platform |
408 |
951 |
|
b. FPOs |
0 |
0 |
|
c. Equity Rights Issues |
1,073 |
6,341 |
|
d. QIPs/IPPs |
110 |
10,106 |
|
e. Preferential Allotments |
4,049 |
4,724 |
|
II. Debt Issues |
95,211 |
1,07,524 |
|
a. Debt Public Issues |
576 |
83 |
|
b. Private Placement of Debt |
94,635 |
1,07,441 |
|
III. REITs/ InvITs |
0 |
0 |
|
a. REITs |
0 |
0 |
|
b. InvITs |
0 |
0 |
|
Total Funds Mobilized (I+II+III) |
1,06,127 |
1,38,222 |
Acknowledgements:
RBI Bulletin (www.bulletin.rbi.org.in), SEBI (www.sebi.gov.in), NSE (www.nseindia.com), BSE (www.bseindia.com)
Disclaimer:
This material has been prepared by the personnel in Vora Corporate Finance which is Investment Banking arm of Vora Management Consultancy Private Limited and looks after Mergers & Acquisitions (M&A), Private Equity (PE), Fund Raising, Debt syndication and Valuations and is based out of Ahmedabad, Gujarat, India. Any views or opinions expressed herein are solely that of individual authors and may differ from view of Vora Management Consultancy Private Limited. This material is proprietary to Vora Management Consultancy Private Limited and is for your personal use only. Any distribution, copy, reprints or forward to others is strictly prohibited.
This material captures the information based on information available in the public domain, public announcements and sources believed to be reliable. Analysis contained herein is based on publicly available information and appropriate assumptions. This material is intended merely to highlight market developments and is not intended to be comprehensive and does not constitute strategic, investment, legal or tax advice. In no event Vora Management Consultancy Private Limited be liable for any use by any party or for any decision made or action taken by any party in reliance upon, or for any inaccuracies or errors in, or omissions from, the information contained herein and such information may not be relied upon by you for evaluating any transaction.